ABIONYX Pharma SA (EPA:ABNX)
France · Delayed Price · Currency is EUR 1.880
+0.024 (1.29%)
Aug 3, 2026, 1:25 PM CET
ABIONYX Pharma Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 3.52 | 3.24 | 4.1 | 4.05 | 7.94 |
Cash & Short-Term Investments | 3.52 | 3.24 | 4.1 | 4.05 | 7.94 |
Cash Growth | 8.84% | -21.17% | 1.43% | -49.01% | -13.32% |
Accounts Receivable | 0.72 | 0.99 | 0.91 | 1.3 | 1.33 |
Other Receivables | 0.86 | 1.3 | 1.58 | 1.76 | 3.29 |
Receivables | 1.59 | 2.3 | 2.5 | 3.05 | 4.62 |
Inventory | 0.26 | 0.21 | 0.22 | 0.15 | 0.18 |
Prepaid Expenses | 0.11 | 0.12 | 0.07 | 0.33 | 0.28 |
Total Current Assets | 5.47 | 5.86 | 6.89 | 7.57 | 13.01 |
Property, Plant & Equipment | 1.8 | 1.98 | 2.22 | 2.56 | 3.07 |
Long-Term Investments | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Goodwill | 5.38 | 5.38 | 5.38 | 5.38 | 5.38 |
Other Intangible Assets | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 |
Other Long-Term Assets | 0.27 | 0.11 | 0.14 | 0.12 | 0.19 |
Total Assets | 13.12 | 13.54 | 14.83 | 15.82 | 21.83 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.52 | 1.63 | 1.44 | 1.85 | 2.71 |
Accrued Expenses | 2.16 | 0.75 | 1.03 | 1.03 | 1.51 |
Short-Term Debt | - | - | 0 | 0 | 0.17 |
Current Portion of Long-Term Debt | 0.45 | 0.5 | 0.5 | 0.49 | 0.49 |
Current Portion of Leases | 0.34 | 0.34 | 0.31 | 0.38 | 0.4 |
Current Income Taxes Payable | 0.14 | 0.18 | - | - | - |
Current Unearned Revenue | 0.55 | 0.29 | 0.59 | 0.38 | 0.43 |
Other Current Liabilities | 0 | 0.01 | 0.06 | 0.96 | 1.04 |
Total Current Liabilities | 5.16 | 3.71 | 3.93 | 5.09 | 6.75 |
Long-Term Debt | 1.96 | 0.61 | 1.1 | 1.42 | 1.65 |
Long-Term Leases | 1.05 | 1.3 | 1.47 | 1.73 | 2.25 |
Pension & Post-Retirement Benefits | 0.43 | 0.41 | 0.41 | 0.42 | 0.5 |
Total Liabilities | 8.6 | 6.03 | 6.91 | 8.65 | 11.16 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1.78 | 1.75 | 1.62 | 1.42 | 1.4 |
Additional Paid-In Capital | 6.29 | 8.61 | 12.57 | 8.6 | 179.21 |
Retained Earnings | -5.55 | -4.38 | -3.52 | -4.21 | -5.82 |
Treasury Stock | -0.08 | -0.25 | -0.19 | - | - |
Comprehensive Income & Other | 2.08 | 1.8 | -2.56 | 1.36 | -164.11 |
Shareholders' Equity | 4.51 | 7.52 | 7.92 | 7.17 | 10.68 |
Total Liabilities & Equity | 13.12 | 13.54 | 14.83 | 15.82 | 21.83 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 3.81 | 2.76 | 3.39 | 4.01 | 4.96 |
Net Cash (Debt) | -0.28 | 0.48 | 0.71 | 0.03 | 2.98 |
Net Cash Growth | - | -33.05% | 2063.64% | -98.89% | -67.39% |
Net Cash Per Share | -0.01 | 0.01 | 0.02 | 0.00 | 0.12 |
Filing Date Shares Outstanding | 35.29 | 34.68 | 32.21 | 28.1 | 27.7 |
Total Common Shares Outstanding | 35.29 | 34.68 | 32.21 | 28.1 | 27.7 |
Working Capital | 0.3 | 2.15 | 2.96 | 2.48 | 6.26 |
Book Value Per Share | 0.13 | 0.22 | 0.25 | 0.26 | 0.39 |
Tangible Book Value | -0.93 | 2.06 | 2.47 | 1.72 | 5.22 |
Tangible Book Value Per Share | -0.03 | 0.06 | 0.08 | 0.06 | 0.19 |